Oncology Pharma Reveals Strategic Plans for Company Growth and Focus
Oncology Pharma (OTC: ONPH) announced its strategic plans for growth, focusing on expanding its cancer therapeutics portfolio through new license agreements and partnerships. The company aims to form financial partnerships to support the development of licensed therapeutic agents. A spokesperson highlighted efforts to align product development with brand identity and mentioned potential financing sources for short and mid-term needs. However, the release also notes several risks, including negative operating cash flows and the need for additional funding.
- Plans to expand cancer therapeutics through new license agreements.
- Aims to form financial partnerships to support development.
- Identified potential financing sources for short and mid-term needs.
- Current negative operating cash flows.
- Need for additional funding to finance operating plans.
- Potentially dilutive financing terms.
SAN FRANCISCO, CA, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) revealed today the Company’s plans for growth and development of its intellectual property and business model. Key focal points include expansion of its cancer therapeutics through acquisition of license agreements and formation of synergistic partnerships and expansion of other niche therapeutics. Also, an important part of the Company’s strategic plans include the goal of forming financial partnerships that allow the development of licensed therapeutic agents.
Oncology Pharma’s spokesperson has stated, “We are looking to expand our products under development in a way that they dovetail together and define our brand. Currently, we have identified potential financing sources for short term and midterm financings.”
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
FORWARD-LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Website: www.oncology-pharma.com
Email: info@oncology-pharma.com
FAQ
What are Oncology Pharma's plans for growth in 2021?
What challenges does Oncology Pharma face?
What is the stock symbol for Oncology Pharma?
How is Oncology Pharma planning to finance its projects?
